Comparative Pharmacology
Head-to-head clinical analysis: PROTRIPTYLINE HYDROCHLORIDE versus SILENOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROTRIPTYLINE HYDROCHLORIDE versus SILENOR.
PROTRIPTYLINE HYDROCHLORIDE vs SILENOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. May also downregulate beta-adrenergic and serotonin receptors.
Selective histamine H1 receptor antagonist; promotes sleep by antagonizing central histaminergic neurotransmission.
15 mg orally 3 to 4 times daily, not to exceed 60 mg per day.
6 mg orally once daily at bedtime, not to exceed 6 mg/day.
None Documented
None Documented
Terminal elimination half-life: 54-92 hours (mean ~74 hours); due to long half-life, steady-state is reached in 11-18 days.
Terminal elimination half-life is approximately 10 hours (range 8-15 hours) in healthy adults; prolonged in elderly and hepatic impairment.
Primarily renal (50-70% as metabolites, <5% unchanged); biliary/fecal elimination accounts for ~10-20%.
Primarily renal (approximately 60% as unchanged drug and metabolites), with 30% fecal elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant